Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Positron Emission Tomography Imaging of Hypoxia.

Literature DB >> 20046923

Positron Emission Tomography Imaging of Hypoxia.

Suzanne E Lapi, Thomas F Voller, Michael J Welch.

Abstract

Hypoxia imaging has applications in functional recovery in ischemic events such as stroke and myocardial ischemia, but especially in tumors in which hypoxia can be predictive of treatment response and overall prognosis. Recently there has been development of imaging agents utilizing positron emission tomography for non-invasive imaging of hypoxia. Many of these PET agents have come to the forefront of hypoxia imaging. Halogenated PET nitroimidazole imaging agents labeled with (18)F (t(1/2) = 110 m) and (124)I (t(1/2) = 110 m) have been under investigation for the last 25 years, with radiometal agents ((64)Cu-ATSM) being developed more recently. This review focuses on these positron emission tomography imaging agents for hypoxia.

Entities: Chemical Disease Gene Species

Year: 2009 PMID： 20046923 PMCID： PMC2751863 DOI： 10.1016/j.cpet.2009.05.009

Source DB: PubMed Journal: PET Clin ISSN： 1556-8598

56 in total

1. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.

Authors: Y Fujibayashi; H Taniuchi; Y Yonekura; H Ohtani; J Konishi; A Yokoyama
Journal: J Nucl Med Date: 1997-07 Impact factor: 10.057

Review 2. Hypoxia in cancer: significance and impact on clinical outcome.

Authors: Peter Vaupel; Arnulf Mayer
Journal: Cancer Metastasis Rev Date: 2007-06 Impact factor: 9.264

3. PET imaging with hypoxia tracers: a must in radiation therapy.

Authors: Giovanni Lucignani
Journal: Eur J Nucl Med Mol Imaging Date: 2008-04 Impact factor: 9.236

4. Imaging of ischemic but viable myocardium using a new 18F-labeled 2-nitroimidazole analog, 18F-FRP170.

Authors: Tomohiro Kaneta; Yoshihiro Takai; Yutaka Kagaya; Yuriko Yamane; Hiroaki Wada; Masahiro Yuki; Ren Iwata; Michihiko Tsujitani; Shoki Takahashi; Shogo Yamada
Journal: J Nucl Med Date: 2002-01 Impact factor: 10.057

5. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors: Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal: J Nucl Med Date: 2005-02 Impact factor: 10.057

Review 6. Tumor microenvironmental physiology and its implications for radiation oncology.

Authors: Peter Vaupel
Journal: Semin Radiat Oncol Date: 2004-07 Impact factor: 5.934

7. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.

Authors: D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst
Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701

8. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

Authors: M Höckel; C Knoop; K Schlenger; B Vorndran; E Baussmann; M Mitze; P G Knapstein; P Vaupel
Journal: Radiother Oncol Date: 1993-01 Impact factor: 6.280

Review 9. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications.

Authors: Bernard Gallez; Christine Baudelet; Bénédicte F Jordan
Journal: NMR Biomed Date: 2004-08 Impact factor: 4.044

10. A marker for hypoxic cells in tumours with potential clinical applicability.

Authors: J D Chapman; A J Franko; J Sharplin
Journal: Br J Cancer Date: 1981-04 Impact factor: 7.640

13 in total

Review 1. An overview of the developments and potential applications of ⁶⁸Ga-labelled PET/CT hypoxia imaging.

Authors: Philippa L Bresser; Mariza Vorster; Mike M Sathekge
Journal: Ann Nucl Med Date: 2021-01-05 Impact factor: 2.668

2. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.

Authors: Olli Eskola; Tove J Grönroos; Sarita Forsback; Johanna Tuomela; Gaber Komar; Jörgen Bergman; Pirkko Härkönen; Merja Haaparanta; Heikki Minn; Olof Solin
Journal: Mol Imaging Biol Date: 2012-04 Impact factor: 3.488

Review 3. Imaging radiation-induced normal tissue injury.

Authors: Mike E Robbins; Judy K Brunso-Bechtold; Ann M Peiffer; Christina I Tsien; Janet E Bailey; Lawrence B Marks
Journal: Radiat Res Date: 2012-02-21 Impact factor: 2.841

Review 4. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors: Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal: Am J Nucl Med Mol Imaging Date: 2014-06-07

Review 5. Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).

Authors: Suzanne E Lapi; Jason S Lewis; Farrokh Dehdashti
Journal: Semin Nucl Med Date: 2015-03 Impact factor: 4.446

6. In vivo retinal and choroidal hypoxia imaging using a novel activatable hypoxia-selective near-infrared fluorescent probe.

Authors: Shinichi Fukuda; Kensuke Okuda; Genichiro Kishino; Sujin Hoshi; Itsuki Kawano; Masahiro Fukuda; Toshiharu Yamashita; Simone Beheregaray; Masumi Nagano; Osamu Ohneda; Hideko Nagasawa; Tetsuro Oshika
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-08-29 Impact factor: 3.117

7. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.

Authors: Stéphanie Servagi-Vernat; Sarah Differding; Francois-Xavier Hanin; Daniel Labar; Anne Bol; John A Lee; Vincent Grégoire
Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-26 Impact factor: 9.236

Positron Emission Tomography Imaging of Hypoxia.

1. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.

Review 2. Hypoxia in cancer: significance and impact on clinical outcome.

3. PET imaging with hypoxia tracers: a must in radiation therapy.

4. Imaging of ischemic but viable myocardium using a new 18F-labeled 2-nitroimidazole analog, 18F-FRP170.

5. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Review 6. Tumor microenvironmental physiology and its implications for radiation oncology.

7. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.

8. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

Review 9. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications.

10. A marker for hypoxic cells in tumours with potential clinical applicability.

Review 1. An overview of the developments and potential applications of ⁶⁸Ga-labelled PET/CT hypoxia imaging.

2. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.

Review 3. Imaging radiation-induced normal tissue injury.

Review 4. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Review 5. Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).

6. In vivo retinal and choroidal hypoxia imaging using a novel activatable hypoxia-selective near-infrared fluorescent probe.

7. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.

8. Prognostic impacts of hypoxic markers in soft tissue sarcoma.

9. Toward noninvasive quantification of adipose tissue oxygenation with MRI.

10. Detecting hypoxia in vitro using ¹⁸F-pretargeted IEDDA "click" chemistry in live cells.

Review 2. Hypoxia in cancer: significance and impact on clinical outcome.

Review 6. Tumor microenvironmental physiology and its implications for radiation oncology.

Review 9. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications.

Review 1. An overview of the developments and potential applications of 68Ga-labelled PET/CT hypoxia imaging.

Review 3. Imaging radiation-induced normal tissue injury.

Review 4. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Review 5. Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).

Review 1. An overview of the developments and potential applications of ⁶⁸Ga-labelled PET/CT hypoxia imaging.